Use of dual antiplatelet therapy (DAPT; the combination of aspirin and an inhibitor of platelet P2Y 12 ) is the key pharmacological component in the management of acute coronary syndrome and percutaneous coronary intervention (PCI) with stent implantation, but the optimal treatment duration is still unclear.
INTRODUCTION
stents (DESs) in reducing restenosis and rate of repeat revascularization as compared with baremetal stents (BMSs) [1, 2] . Although DESs were widespread and worked as a default device strategy in the majority of patients receiving percutaneous coronary intervention (PCI) for more than a decade, there was a considerable concern regarding late stent thrombosis (ST) [3] [4] [5] [6] . Pathologic studies suggested that incomplete endothelialization of DESs was frequently observed even after 6 or 12 months after PCI [7] [8] [9] , and clinically, most of thrombotic events tended to occur in the first 6-12 months after procedure and sometimes happened after the first year after DES implantation [5, 6] . As a result, prolonged use of dual antiplatelet therapy (DAPT) has become prevalent in clinical practice; however, careful balancing between ischemic benefits and bleeding risks according to the duration of DAPT has been an issue for several years [10] [11] [12] .
On the basis of cumulative evidence, the current guidelines recommend that DAPT should be given either for 6-12 months (European guidelines [13] ) or for at least 12 months (U.S. guidelines [14] ) after DES implantation unless patients are at high risk for bleeding. However, these recommendations are largely based on registry data and randomized trials with a limited number of patients, and therefore the optimal duration of DAPT remains in question. Up to recently, several clinical studies have been performed to address questions about the optimal duration of DAPT in patients who have received DESs [15] [16] [17] [18] [19] [20] [21] . This article systemically reviews the current evidence from available clinical studies with the aim of helping physicians to make decisions on the optimal duration of DAPT for patients who are undergoing DES implantation. and Euro-PCR were searched. There was no language restriction for the search. We excluded studies with number of enrolled patients less than 500. The search process was fairly extensive, and efforts were made to obtain the longest reported follow-up data from a combination of sources.
DISCUSSION

Longer Is Better
There were several observational studies (not, randomized clinical trials) that supported relatively longer duration, more than 12 months of DAPT after DES implantation.
Those were mostly from the early experiences of DESs which implies that these were data from the first-generation DES. Brief summary of each study design and primary results are summarized in Table 1 [22] [23] [24] [25] [26] .
A first safety concern with regard to DES implantation without long-term maintenance of clopidogrel was raised by data from the Basel Stent KostenEffektivitäts Trial-Late Thrombotic Events (BASKET-LATE) (ISRCTN75663024) [22] . This study intended to define the incidence of late clinical events
[cardiac death or myocardial infarction (MI)]
and late ST in patients treated with the firstgeneration DESs versus BMSs after the discontinuation of clopidogrel and showed that more thrombotic events were found to occur 7-18 months after the procedure during the period with absence of DAPT, which were twice as frequent after DESs than BMSs. A subsequent, observational study from Duke registry highlighted the apparent benefits of extended clopidogrel use after first-generation [25] . The SWEDEHEART(NCT01623700) registry data showed that[6 months of DAPT compared with 6 months of DAPT among acute coronary syndrome (ACS) patients was associated with a lower risk of death, stroke, or re-infarction (HR 0.75, 95% CI 0.59-0.95) [26] . Even in the subgroup analysis, with less than 6-month duration of DAPT, more than 3 months of DAPT lowered the risk of death, stroke, or re-infarction (HR 0.84, 95% CI 0.75-0.95) compared to less than 3 months of DAPT.
Shorter Is Better
By contrast, some observational studies and randomized trials suggested the safety and efficacy of shorter duration (less than 6-12 months) of DAPT would be comparable or better in safety outcomes compared to longer duration of DAPT among patients receiving DES implantation. Summary of these studies is shown in Table 2 [4, 5, [16] [17] [18] [19] [20] [21] 27 ].
Observational Studies
Airoldi et al. [4] suggested that discontinuation of thienopyridine therapy was the key determinant of ST occurrence within the first 6 months, but not longer than 6-month period.
They suggested that a vulnerable period of ST associated with DAPT continuation would be within 6 months. Schulz et al. [5] also demonstrated that the discontinuation of clopidogrel was a strong predictor for ST within the first 6 months but not thereafter after the first-generation DES implantation. The Two-Year Clopidogrel Need (TYCOON) study which is also based on the first-generation DES data, suggested that there was no long-term survival benefit in 24 months of DAPT compared to 12 months of DAPT, although early discontinuation of DAPT was the important predictor of ST (1% vs. 3%, p = 0.02) [27] . were event free within 1 year after DES implantation to receive DAPT or aspirin alone [17] . At 24 months, no difference was observed in the primary endpoint (composite of cardiac death or MI) or the risk for ST. However, [30, 31] . A total of 4,081 patients received DAPT for 3-6 months, and 4,076 patients were treated with DAPT for 12-24 months. There was no significant difference in the rate of the composite of cardiac death or MI between the short and prolonged DAPT groups (3.3% vs. Currently, an increasing number of patients are receiving the second-generation P2Y 12 inhibitors (prasugrel or ticagrelor) instead of clopidogrel which demonstrate more potent suppression of platelet activity, leading to reduction of recurrent ischemic events [37, 38] .
Based on these results, recent guidelines recommended prasugrel and ticagrelor on equal terms with clopidogrel in the patient with ACS or stent implantation [13] . However, studies on optimal duration of DAPT with these should be discontinued abruptly or with a progressive downgraded dosing [36] . Patients with planned discontinuation of chronic Upcoming results of much larger, double blind, and randomized clinical trials, with a higher use of second-and newer generation DESs will guide the physician in making informed decisions on the optimal duration of DAPT for patients receiving DES implantation. In addition, more data would be required to define the role of newer generation P2Y 12 inhibitors, including ticagrelor and prasugrel, for diverse clinical settings.
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